叉头转录因子家族在肝内胆管细胞癌中的应用前景

摘要/Abstract

摘要： 肝内胆管细胞癌(ICC)是肝内第二大恶性肿瘤,具有起病隐匿、预后差等特征,大多数患者发现时已处于晚期,错过最佳治疗时间。既往研究表明,叉头转录因子(FOX)家族在癌症的发生、发展、迁移及侵袭等生物学功能中发挥重要作用。因此,本文对FOX家族生物学功能及其在不同肿瘤中的研究进展进行综述,以期为靶向治疗ICC提供新思路。

王童舒, 周敏, 付朝旭, 刘慧敏, 朴红心. 叉头转录因子家族在肝内胆管细胞癌中的应用前景[J]. 肝脏, 2025, 30(7): 1010-1012.

/ 推荐

[1] 张宁,卢姗姗,Rifaat Safadi,等.肝内胆管细胞癌诊断及治疗的现状与挑战[J].传染病信息,2018,31(1):24-30.
[2] Primrose J N, Fox R P, Palmer D H, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study[J]. Lancet Oncol, 2019,20(5):663-673.
[3] Granadino B, Perez-Sanchez C, Rey-Campos J. Fork head transcription factors[J].Curr Genom,2000,1:353-382.
[4] Weigel D, Jürgens G, Küttner F, et al. The homeotic gene fork head encodes a nuclear protein and is expressed in the terminal regions of the Drosophila embryo[J]. Cell, 1989,19,57(4):645-658.
[5] Myatt S S, Lam E W. The emerging roles of forkhead box (Fox) proteins in cancer[J].Nat Rev Cancer,2007;7(11):847-859.
[6] Jozwik K M, Carroll J S. Pioneer factors in hormone-dependent cancers[J].Nat Rev Cancer,2012,12(6):381-385.
[7] Liu Y, Yu K, Kong X,et al. FOXA1 O-GlcNAcylation-mediated transcriptional switch governs metastasis capacity in breast cancer[J]. Sci Adv,2023,9(33): 7112.
[8] Del Giudice M, Foster J G, Peirone S, et al. FOXA1 regulates alternative splicing in prostate cancer[J]. Cell Rep,2022,40(13):111404.
[9] Yuan Z, Ye M, Qie J, et al. FOXA1 promotes cell proliferation and suppresses apoptosis in HCC by directly regulating miR-212-3p/FOXA1/AGR2 signaling pathway[J]. Onco Targets Ther,2020,9(13):5231-5240.
[10] He S, Zhang J, Zhang W, et al. FOXA1 inhibits hepatocellular carcinoma progression by suppressing PIK3R1 expression in male patients[J]. Exp Clin Cancer Res,2017,36(1):175.
[11] Tang Y, Shu G, Yuan X, et al. FOXA2 functions as a suppressor of tumor metastasis by inhibition of epithelial-to-mesenchymal transition in human lung cancers[J]. Cell Res,2011,21(2):316-326.
[12] Wang J, Zhu C P, Hu P F, et al. FOXA2 suppresses the metastasis of hepatocellular carcinoma partially through matrix metalloproteinase-9 inhibition[J]. Carcinogenesis,2014,35(11):2576-2583.
[13] Zhan X, Zhao A. Transcription factor FOXA3 promotes the development of hepatoblastoma via regulating HNF1A, AFP, and ZFHX3 expression[J]. Clin Lab Anal,2021,35(3):e23686.
[14] Xu Z Y, Ding S M, Zhou L, et al. FOXC1 contributes to microvascular invasion in primary hepatocellular carcinoma via regulating epithelial-mesenchymal transition[J]. Int J Biol Sci,2012,8(8):1130-1141.
[15] Wang J, Li L, Liu S, et al. FOXC1 promotes melanoma by activating MST1R/PI3K/AKT[J]. Oncotarget,2016,7(51):84375-84387.
[16] Mosharaf M P, Reza M S, Gov E, et al. Disclosing potential key genes, therapeutic targets and agents for non-small cell lung cancer: evidence from integrative bioinformatics analysis[J].Vaccines (Basel),2022,10(5):771.
[17] Yang F, Lv L, Zhang K, et al. Elevated FOXC2 expression promotes invasion of HCC cell lines and is associated with poor prognosis in hepatocellular carcinoma[J]. Cell Physiol Biochem,2017,44(1):99-109.
[18] Wang Z, Banerjee S, Kong D, et al. Down-regulation of Forkhead Box M1 transcription factor leads to the inhibition of invasion and angiogenesis of pancreatic cancer cells[J]. Cancer Res,2007,67(17):8293-300.
[19] Wang I C, Chen Y J, Hughes D E, et al. FoxM1 regulates transcription of JNK1 to promote the G1/S transition and tumor cell invasiveness[J].Biol Chem,2008,283(30):20770-20778.
[20] Zona S, Bella L, Burton M J,et al. FOXM1: an emerging master regulator of DNA damage response and genotoxic agent resistance. Biochim Biophys Acta[J]. 2014,1839(11):1316-1322.
[21] 王玉萍,刘约瑟,张玉珂,等.FOXM1通过调节KIF20A介导巨噬细胞M2极化对食管鳞状细胞癌细胞的作用[J].中国老年学杂志,2024,44(7):1661-1668.
[22] Yang Q, Wu F, Zhang Y, et al. FOXM1 regulates glycolysis in nasopharyngeal carcinoma cells through PDK1[J]. J Cell Mol Med,2022,26(13):3783-3796.
[23] Hu G, Yan Z, Zhang C,et al. FOXM1 promotes hepatocellular carcinoma progression by regulating KIF4A expression[J]. Exp Clin Cancer Res,2019,38(1):188.
[24] Qin Q, Chen H, Xu H,et al. FoxM1 knockdown enhanced radiosensitivity of esophageal cancer by inducing apoptosis[J]. Cancer,2023,14(3):454-463.
[25] Yang Y, Jiang H, Li W, et al. FOXM1/DVL2/Snail axis drives metastasis and chemoresistance of colorectal cancer[J]. Aging (Albany NY),2020,12(23):24424-24440.
[26] Yan L, Sun H, Chen Y, et al. FOXP2 suppresses the proliferation, invasion, and aerobic glycolysis of hepatocellular carcinoma cells by regulating the KDM5A/FBP1 axis[J]. Environ Toxicol,2024,39(1):341-356.
[27] Saleh R, Elkord E. FoxP3⁺T regulatory cells in cancer: prognostic biomarkers and therapeutic targets[J]. Cancer Lett,2020,490:174-185.
[28] Shi J, Wang J, Cheng H, et al. FOXP4 promotes laryngeal squamous cell carcinoma progression through directly targeting LEF1[J].Mol Med Rep,2021,24(6):831.
[29] Bhat U G, Halasi M, Gartel A L. Thiazole antibiotics target FoxM1 and induce apoptosis in human cancer cells[J].PLoS One,2009,4(5):e5592.
[30] Han X Y, Zhou Z Y, Li S Y, et al. Advances in inhibitors of potential tumor target FOXM1[J].Future Med Chem,2023,15(10):809-812.
[31] Song B, Park S H, Zhao J C, et al. Targeting FOXA1-mediated repression of TGF-β signaling suppresses castration-resistant prostate cancer progression[J].J Clin Invest,2019,129(2):569-582.
[32] Mccann J J, Vasilevskaya I A, Mcnair C, et al. Mutant p53 elicits context-dependent pro-tumorigenic phenotypes[J]. Oncogene, 2022, 41(3): 444-458.

叉头转录因子家族在肝内胆管细胞癌中的应用前景

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 11

编辑推荐

Metrics

本文评价

[1]	刘萍, 吴仁梅, 彭粤如. 超声造影各期增强特点在肝内胆管细胞癌与肝细胞癌、肝血管瘤鉴别诊断中的价值[J]. 肝脏, 2024, 29(6): 662-666.
[2]	赵喜君, 杨宁. 肝内胆管细胞癌的综合治疗[J]. 肝脏, 2023, 28(9): 1020-1023.
[3]	程丽, 李江山, 孙小伶. MRI及MSCT用于肝内胆管细胞癌临床诊断的效能分析[J]. 肝脏, 2023, 28(11): 1314-1318.
[4]	瓦增成, 杜婷, 许惠晴, 乔志忠. 常规超声和超声造影对肝泡状棘球蚴病和肝内胆管细胞癌的鉴别诊断[J]. 肝脏, 2022, 27(5): 547-549.
[5]	李慧娟, 杨立品, 赵莎莎. 淋巴管、血管及神经侵犯对肝内胆管细胞癌术后复发和生存的影响[J]. 肝脏, 2022, 27(4): 466-469.
[6]	朱婷, 林立平, 韦玉亚. 超声造影成像特征及定量参数鉴别肝脏炎性假瘤与肝内胆管细胞癌的价值[J]. 肝脏, 2022, 27(3): 292-295.
[7]	阿卜来海提, 马森林, 陈明泉. CPS1及其LncRNA在胆管细胞癌诊治中的研究进展[J]. 肝脏, 2022, 27(3): 373-375.
[8]	何海涛, 刘尚大, 韦广旭, 许康祥, 周鹏程. 对比DEB-TACE与cTACE治疗不可切除的肝内胆管细胞癌的有效性及安全性[J]. 肝脏, 2022, 27(12): 1292-1295.
[9]	刘念, 刘劲梧. ¹²⁵I粒子植入联合TIPS术治疗肝内胆管细胞癌门静脉主干癌栓合并门静脉高压的临床分析[J]. 肝脏, 2021, 26(10): 1115-1118.
[10]	李银珍, 杜日昌, 丁宇, 徐彤, 廖罗飞. 肝内胆管细胞癌患者EGFR和Her-2表达水平评估预后的应用价值[J]. 肝脏, 2020, 25(6): 614-616.
[11]	刘明, 黄磊. 经肝动脉化疗栓塞术治疗经手术切除的肝内胆管细胞癌复发患者的疗效[J]. 肝脏, 2019, 24(5): 563-565.